论文部分内容阅读
目的观察局部晚期宫颈癌患者采取同步放化疗治疗的临床效果及不良反应。方法选取170例局部晚期宫颈癌患者,并随机分为两组,85例采取同步放化疗为观察组,85例采取单纯放射治疗为对照组,分别对两组患者近期疗效、远期疗效及不良反应发生情况进行统计分析。结果观察组治疗总有效率为60.00%,对照组治疗总有效率为41.18%,两组差异有统计学意义(P﹤0.05)。随访所有患者1～3年期间,观察组复发率明显低于对照组,3年生存率明显高于对照组,差异有统计学意义(P﹤0.05)。观察组35(41.17%)例早期发生消化道症状,对照组15(17.6%)例早期发生消化道症状,差异有统计学意义(P﹤0.05)。观察组早期结直肠反应、膀胱反应发生率分别为17.6%(15/85)和15.29%(13/85),对照组分别为15.29%(13/85)和12.94%(11/85),观察组10.59%(9/85)发生放射性直肠炎,对照组7.06%(6/85)发生放射性直肠炎,两组比较差异均无统计学意义。结论局部晚期宫颈癌患者采用同步放化疗治疗,可提高肿瘤局部控制率,提高短期生存率,而且化疗引起的不良反应患者能耐受,不影响放疗进程,值得临床推广使用。
Objective To observe the clinical effects and side effects of concurrent chemoradiotherapy in patients with locally advanced cervical cancer. Methods A total of 170 patients with locally advanced cervical cancer were enrolled and divided into two groups at random. Eighty-five patients were treated with concurrent chemoradiation and 85 were treated with radiotherapy alone. The short-term curative effect, long-term curative effect, Response to the occurrence of statistical analysis. Results The total effective rate was 60.00% in the observation group and 41.18% in the control group, the difference was statistically significant (P <0.05). All cases were followed up for 1 to 3 years, the observation group recurrence rate was significantly lower than the control group, 3-year survival rate was significantly higher than the control group, the difference was statistically significant (P <0.05). Gastrointestinal symptoms were observed in 35 (41.17%) cases in the observation group and 15 (17.6%) cases in the control group, with significant difference (P <0.05). In the observation group, the incidence of early colorectal reaction and bladder reaction were 17.6% (15/85) and 15.29% (13/85) respectively, while those in the control group were 15.29% (13/85) and 12.94% (11/85) respectively. Radiation proctitis occurred in 10.59% (9/85) of patients and in 7.06% (6/85) of patients in control group. There was no significant difference between the two groups. Conclusions The treatment of locally advanced cervical cancer with concurrent chemoradiotherapy can improve the local control rate of tumor and improve the short-term survival rate. And patients with adverse reactions caused by chemotherapy can tolerate without affecting the course of radiotherapy, which is worthy of clinical promotion.